Markets

The Long Case For Synergy Pharmaceuticals Inc. (SGYP)

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) seems to be forming a pattern of major movements, providing only some crumbs of outlook for market participants trying to figure out its next move. Now trading with a market value of 431.66M, the company has a mix of catalysts and obstacles that spring from the nature of its operations. As the day-to-day narrative ebbs and flows for this company, it is more important than ever to step back and get a bird’s eye view of the fundamental reality under the surface of this story.

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) Fundamentals That Matter

It’s generally a good idea to start with the most fundamental piece of the picture: the balance sheet. The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For SGYP, the company currently has 98.66 million of cash on the books. The trend over time is important to note. In this case, the company’s debt has been growing. The company also has 132.65 million in total assets, balanced by 171.28 million in total liabilities, which should give you a sense of the viability of the company under any number of imagined business contexts.

Synergy Pharmaceuticals Inc. (SGYP) saw -35.86 million in free cash flow last quarter, representing a quarterly net change in cash of -38.33 million. Perhaps most importantly where cash movements are concerned, the company saw about -35.75 million in net operating cash flow.

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) Revenue Growth Potential

As far as key trends that demonstrate something of the future investment potential of this stock, we need to take a closer look at the top line, first and foremost. Last quarter, the company saw 8.59 million in total revenues. That represents a quarterly year/year change in revenues of 0.00 in sequential terms, the SGYP saw sales decline by -0.09.



But what about the bottom line? After all, that’s what really matters in the end. Synergy Pharmaceuticals Inc. (SGYP) is intriguing when broken down to its core data. The cost of selling goods last quarter was 3.7 million, yielding a gross basic income of 4.88 million. For shareholders, given the total diluted outstanding shares of 246.66 million, this means overall earnings per share of -0.15. Note, this compares with a consensus analyst forecast of -0.15 in earnings per share for its next fiscal quarterly report.

Is Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) Valuation Attractive

Looking ahead at valuations, according to the consensus, the next fiscal year is forecast to bring about -0.28 in total earnings per share. If we consider a median price to earnings ratio on the stock, that corresponds with a stock price of 9,999. However, one should always remember: the trends are more important than the forecasts. This continues to be an interesting story, and we look forward to updating it again soon on Synergy Pharmaceuticals Inc..

Previous ArticleNext Article

Related Post

Why You Should Want To Trade WPX Energy, Inc. (WPX... It's worth it to have a look at WPX Energy, Inc. (NYSE:WPX) as there may be a chasm between the bulls and the bears as far as recent trading activity ...
Aspen Technology, Inc. (AZPN) Sends Strong Signals... Aspen Technology, Inc. (NASDAQ:AZPN) gained 5.67% during trading on Friday, going up from its prior closing price of $56.65 to $59.86 The stock price ...
Fundamentals in Focus for Noble Corporation plc (N... Noble Corporation plc (NYSE:NE)'s interesting series of developments are underway around the US stock market these days. Now trading with a market val...
Dissecting the Insider Trading Patterns of PBF Ene... Recent insider trends for PBF Energy Inc. (NYSE:PBF) have caught the attention of investors. Analysts monitor insider data to understand the sentiment...
Stryker Corporation (SYK): How Do the Books Stack ... Stryker Corporation (NYSE:SYK) has recently been identified as an interesting stock but more in-depth monitoring is needed for a trade decision. Now t...